Skip to main content
. Author manuscript; available in PMC: 2016 Nov 17.
Published in final edited form as: J Am Coll Cardiol. 2015 Nov 17;66(20):2159–2169. doi: 10.1016/j.jacc.2015.09.007

Figure 2. Comparison of Markers of Subclinical Vascular and Renal Damage Among Participants with WCH, MH, SH, and the Control Group.

Figure 2

(A) APWV (62 WCH, 341 MH, 254 SH, and 1,347 NT in the untreated [control] group; 27 WCH, 109 MH, 128 SH, 145 NT among the treated group). (B) Cystatin C Level (69 WCH, 381 MH, 276 SH, and 1,443 NT in the untreated group; 30 WCH, 118 MH, 144 SH, and 167 NT in the treated group). (C) UACR (73 WCH, 389 MH, 292 SH, and 1,516 NT in the untreated group; 31 WCH, 126 MH, 153 SH, and 175 in the treated group). APWV = aortic pulse wave velocity; BMI = body mass index; BP = blood pressure; NT = normotension; SH = sustained hypertension; UACR = urinary albumin to creatinine ratio. Other abbreviations as in Figure 1.

*p < 0.05 compared with NT after adjustment for age, sex, race, BMI, smoking, and diabetes.

†p < 0.01 compared with NT after adjustment for age, sex, race, diabetes, self-reported hypertension, home systolic BP, estimated glomerular filtration rate, high-sensitivity C-reactive protein, and allometric height

‡p < 0.05 compared with NT after adjustment for age, sex, race, diabetes, self-report hypertension, home systolic BP, estimated glomerular filtration rate, high sensitivity C-reactive protein, and allometric height